+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Calquence"

Mantle Cell Lymphoma Therapeutics Market Report 2025 - Product Thumbnail Image

Mantle Cell Lymphoma Therapeutics Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Small Lymphocytic Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

Small Lymphocytic Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 140 Pages
  • Global
From
Mantle Cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

Mantle Cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 138 Pages
  • Global
From
CALQUENCE Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

CALQUENCE Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • November 2023
  • 30 Pages
  • Global
From
Lymphoma Therapeutics Market Size, Share & Industry Trends Analysis Report By Treatment Type, By Disease Type, By Route of Administration (Injectable, and Oral Route), By Distribution Channel, By Regional Outlook and Forecast, 2023-2029 - Product Thumbnail Image

Lymphoma Therapeutics Market Size, Share & Industry Trends Analysis Report By Treatment Type, By Disease Type, By Route of Administration (Injectable, and Oral Route), By Distribution Channel, By Regional Outlook and Forecast, 2023-2029

  • Report
  • April 2023
  • 260 Pages
  • Global
From
  • 5 Results (Page 1 of 1)
Loading Indicator

Calquence (acalabrutinib) is a prescription medication used to treat certain types of B-cell non-Hodgkin lymphoma (NHL). It is a Bruton's tyrosine kinase (BTK) inhibitor, which works by blocking the activity of BTK, a protein that helps B-cells grow and divide. Calquence is approved for use in combination with other medications to treat adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It is also approved for use as a monotherapy to treat adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The Calquence market is a rapidly growing segment of the lymphoma drug market. It is a highly competitive market, with several companies offering similar products. Companies in the Calquence market include AstraZeneca, AbbVie, Gilead Sciences, and Janssen Pharmaceuticals. Show Less Read more